Home › Research › Down syndrome and Alzheimer's
[The significance of measurement of contents of serum serine protease inhibitors in senile dementia of the Alzheimer type]
Amari M, Matsubara E, Ishiguro K, Shoji M, Hirai S.. Rinsho shinkeigaku = Clinical neurology, 1989-10-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
We have evaluated serum alpha 1-antichymotrypsin content in dementia of the Alzheimer type (DAT). The subjects consisted of 26 patients with DAT, 15 with cerebrovascular dementia, 10 with mixed type dementia, 2 with Down syndrome, 17 with Parkinson disease, 14 with spinocerebellar degeneration, 14 with cerebrovascular disease without dementia, 12 with Duchenne muscular dystrophy and 77 normal controls. DAT group showed statistically significant increase of serum alpha 1-antichymotrypsin content, as compared with normal control group (p less than 0.001), mixed type dementia group (p less than 0.05) and other 6 groups (p less than 0.001). However, the levels of both alpha 1-antitrypsin content and inter-alpha-trypsin inhibitor content, included in serine protease inhibitors, were not significantly different between DAT and normal control groups. These findings indicated that measurement of serum alpha 1-antichymotrypsin is useful as the diagnostic marker of DAT.
What this study adds
Evidence grade: Low
The record lists 26 participants. This study found that serum alpha 1-antichymotrypsin was significantly higher in people with dementia of the Alzheimer type than in controls, while alpha 1-antitrypsin and inter-alpha-trypsin inhibitor levels did not differ. The authors suggest this measurement may be useful as a diagnostic marker, not as a treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Amari, M., Matsubara, E., Ishiguro, K., Shoji, M., & Hirai, S. (1989). [The significance of measurement of contents of serum serine protease inhibitors in senile dementia of the Alzheimer type]. Rinsho shinkeigaku = Clinical neurology.
Vancouver
Amari M, Matsubara E, Ishiguro K, Shoji M, Hirai S. [The significance of measurement of contents of serum serine protease inhibitors in senile dementia of the Alzheimer type]. Rinsho shinkeigaku = Clinical neurology. 1989. PMID: 2605832.
BibTeX
@article{amari1989-2605832,
author = {Amari, M. and Matsubara, E. and Ishiguro, K. and Shoji, M. and Hirai, S.},
title = {{[The significance of measurement of contents of serum serine protease inhibitors in senile dementia of the Alzheimer type]}},
journal = {Rinsho shinkeigaku = Clinical neurology},
year = {1989},
pmid = {2605832}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- DAT group showed statistically significant increase of serum alpha 1-antichymotrypsin content, as compared with normal control group (p less than 0.001), mixed type dementia group (p less than 0.05) and other 6 groups (p less than 0.001).
- However, the levels of both alpha 1-antitrypsin content and inter-alpha-trypsin inhibitor content, included in serine protease inhibitors, were not significantly different between DAT and normal control groups.
- These findings indicated that measurement of serum alpha 1-antichymotrypsin is useful as the diagnostic marker of DAT.
Why it matters
This study found that serum alpha 1-antichymotrypsin was significantly higher in people with dementia of the Alzheimer type than in controls, while alpha 1-antitrypsin and inter-alpha-trypsin inhibitor levels did not differ. The authors suggest this measurement may be useful as a diagnostic marker, not as a treatment, cure or prevention.
Study details
- Participants26
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, impact for its field and year and institution's track record, so those were left out: it earned 27 of the 87 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Rinsho shinkeigaku = Clinical neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1989 — older than 20 years, still counted |
| Sample size | 1 / 4 | 26 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.1 citations a year over 39 year(s) since 1989 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Shigekazu Hirai: h-index 6 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 2605832) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 87 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 27 of the 87 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.